Analyst Ratings for Treace Medical Concepts
Portfolio Pulse from Benzinga Insights
Treace Medical Concepts (NASDAQ:TMCI) received 5 analyst ratings in the last quarter, with 4 being bullish and 1 indifferent. The average 12-month price target is $23.2, representing a 5.31% decrease from the previous target of $24.50. Analysts use various methods to forecast stock performance, and their ratings can influence market behavior.
November 10, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Treace Medical Concepts has a predominantly bullish outlook from analysts with a revised average price target of $23.2, indicating a slight decrease in optimism.
The majority of analysts are bullish on TMCI, which could be a positive signal for investors. However, the decrease in the average price target suggests a tempered expectation for future stock performance. Analyst ratings can influence investor sentiment and stock prices in the short term, but the actual impact may vary depending on broader market conditions and company performance.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100